The North America glucose monitoring devices market is expected to grow from US$ 5,987.78 million in 2022 to US$ 14,409.58 million by 2030. It is estimated to grow at a CAGR of 11.6% from 2022 to 2030.
Based on type, the North America glucose monitoring devices market is segmented into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on application, the North America glucose monitoring devices market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on testing site, the North America glucose monitoring devices market is segmented into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on end user, the North America glucose monitoring devices market is segmented into healthcare setting and self/homecare. The self/homecare segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on country, the North America glucose monitoring devices market is segmented int o the US, Canada, and Mexico. The US dominated the North America glucose monitoring devices market in 2022.
B. Braun SE, F. Hoffmann-La Roche Ltd, LifeScan Inc, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, and GE HealthCare Technologies Inc, and Terumo Corp are some of the leading companies operating in the North America glucose monitoring devices market.
Rapid Technological Advancements in Glucose Monitoring Devices Fuel North America Glucose Monitoring Devices Market
Products with advanced technologies offer more effective benefits in diabetes treatment. As the prevalence of diabetes increases worldwide, the demand for more products with advancements also accelerates. Thus, researchers have been carrying out research activities resulting in product innovations over the years. There are many methods to deliver insulin into the body, such as needles, insulin pens, and insulin pumps. Insulin pumps are small, computerized diabetes management devices connected with a cannula under the skin to deliver a slow, continuous insulin level. The individual can control the program depending on the requirements. Optimal diabetes management depends on accurate glucose monitoring devices. The increasing advancements in glucose monitoring devices have resulted in smaller required blood volumes with improved accuracy. The ability to transfer data between the blood glucose meter and glucose monitoring devices has also been improved. The increasing advancements in blood glucose monitoring technology have improved accuracy, smaller required blood volumes, and the ability to transfer data between the blood glucose meter and glucose monitoring devices. In June 2022, Abbott announced a new bio wearable that continuously monitors glucose and ketone levels in one sensor. Thus, the technological advancements coupled with the increasing influx of new products are expected to propel the market growth over the forecast years.North America Glucose Monitoring Devices Market Overview
The North America North America glucose monitoring devices market has been segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the rising diabetic prevalence, and increasing geriatric population are main factors positively influencing the growth of the market. Additionally, technological advancements in monitoring devices further enhances the overall market growth during 2022-2030.North America Glucose Monitoring Devices Market Revenue and Forecast to 2030 (US$ Million)
North America Glucose Monitoring Devices Market Segmentation
The North America glucose monitoring devices market is segmented into type, application, testing site, end- user, and country.Based on type, the North America glucose monitoring devices market is segmented into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on application, the North America glucose monitoring devices market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on testing site, the North America glucose monitoring devices market is segmented into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on end user, the North America glucose monitoring devices market is segmented into healthcare setting and self/homecare. The self/homecare segment held a larger share of the North America glucose monitoring devices market in 2022.
Based on country, the North America glucose monitoring devices market is segmented int o the US, Canada, and Mexico. The US dominated the North America glucose monitoring devices market in 2022.
B. Braun SE, F. Hoffmann-La Roche Ltd, LifeScan Inc, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, and GE HealthCare Technologies Inc, and Terumo Corp are some of the leading companies operating in the North America glucose monitoring devices market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. North America Glucose Monitoring Devices Market - Key Industry Dynamics
5. Glucose Monitoring Devices Market - North America Market Analysis
6. North America Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by Type
7. North America Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by Application
8. North America Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by Testing Site
9. North America Glucose Monitoring Devices Market - Revenue and Forecast to 2030 - by End User
10. North America Glucose Monitoring Devices Market - Revenue and Forecast to 2030 -Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Executive Summary
At 11.6% CAGR, the North America Glucose Monitoring Devices Market is Speculated to be Worth US$ 14,409.58 million by 2030.According to this research, the North America glucose monitoring devices market was valued at US$ 5,987.78 million in 2022 and is expected to reach US$ 14,409.58 million by 2030, registering a CAGR of 11.6% from 2022 to 2030. Rising incidence of diabetes is a critical factor attributed to the North America glucose monitoring devices market expansion.
Diabetes is a life-threatening chronic disease with no specialized cure. It is mainly caused by the body’s inability to produce or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. There are two types of diabetes - diabetes type-I (also known as diabetes insipidus) and diabetes type-II (also termed diabetes mellitus). The incidence and prevalence of diabetes are steadily increasing across the world. Type 2 diabetes is the most prevalent form of diabetes and has increased alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to International Diabetes Federation (IDF), approximately 537 million people were living with diabetes in 2022 and is expected to reach 738 million by 2045 globally. Patients suffering from diabetes require frequent monitoring and external administration of insulin. The rising prevalence of diabetes across the globe is driving the growth of the North America glucose monitoring devices market.
On the contrary, high cost of glucose monitoring devices hampers the North America glucose monitoring devices market.
Based on type, the North America glucose monitoring devices market is bifurcated into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices held 59.5% share of North America glucose monitoring devices market in 2022, amassing US$ 3,561.70 million. It is projected to garner US$ 8,387.68 million by 2030 to expand at 11.3% CAGR during 2022-2030.
Based on application, the North America glucose monitoring devices market is bifurcated into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held 69.6% share of North America glucose monitoring devices market in 2022, amassing US$ 4,170.21 million. It is projected to garner US$ 9,949.40 million by 2030 to expand at 11.5% CAGR during 2022-2030.
Based on testing site, the North America glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held 70.2% share of North America glucose monitoring devices market in 2022, amassing US$ 4,205.77 million. It is projected to garner US$ 10,403.89 million by 2030 to expand at 12.0% CAGR during 2022-2030.
Based on end user, the North America glucose monitoring devices market is bifurcated into healthcare setting and self/homecare. The self/homecare segment held 66.8% share of North America glucose monitoring devices market in 2022, amassing US$ 3,997.99 million. It is projected to garner US$ 9,335.15 million by 2030 to expand at 11.2% CAGR during 2022-2030.
Based on country, the North America glucose monitoring devices market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 82.7% share of North America glucose monitoring devices market in 2022. It was assessed at US$ 4,951.02 million in 2022 and is likely to hit US$ 12,135.85 million by 2030, exhibiting a CAGR of 11.9% during 2022-2030.
Key players operating the North America glucose monitoring devices market are B. Braun SE, F. Hoffmann-La Roche Ltd, LifeScan Inc, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, GE HealthCare Technologies Inc, and Terumo Corp, among others.
In June-2022, Roche's Accu-Chek Inform II hospital blood glucose system was approved by Health Canada for intensive care use. The Accu-Chek Inform II solution has brought and continues to bring high-end laboratory standards to bedside glucose testing and helps ensure the safety of patients. In Oct-2022, Life Scan launched OneTouch Solutions, an eCommerce site offering a comprehensive and convenient choice of personalized wellness programs to help people manage diabetes. OneTouch Solutions is available to US consumers and offered to healthcare providers, payors, and employers as a reimbursed adjudicated option.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- B. Braun SE
- F. Hoffmann-La Roche Ltd
- LifeScan Inc
- Medtronic Plc
- Abbott Laboratories
- Ypsomed Holding AG
- Senseonics Holdings Inc
- Nipro Corp
- GE HealthCare Technologies Inc
- Terumo Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 99 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value in 2022 | 5.99 Billion |
| Forecasted Market Value by 2030 | 14.41 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | North America |
